EXACT SCIENCES CORPORATION (NASDAQ:EXAS) Files An 8-K Other Events

38

EXACT SCIENCES CORPORATION (NASDAQ:EXAS) Files An 8-K Other Events
Item 8.01 below.

The information furnished in Item 7.01 of this Current Report on Form8-K, including Exhibit99.1 attached hereto, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

8.01 Other Events.

On January11, 2017, the Company issued a press release announcing the commencement of a registered underwritten public offering of $500 million aggregate principal amount of convertible senior notes due 2025. A copy of the press release is attached as Exhibit99.2 to this Current Report on Form8-K.

9.01. Financial Statements and Exhibits.

Exhibits

The exhibits to this Current Report on Form8-K are listed in the ExhibitIndex attached hereto and incorporated herein by reference.


EXACT SCIENCES CORP Exhibit
EX-99.1 2 a18-2706_3ex99d1.htm EX-99.1 Exhibit 99.1   EXACT SCIENCES CORPORATION   SUPPLEMENTAL REGULATION FD DISCLOSURE   DATED JANUARY 11,…
To view the full exhibit click here

About EXACT SCIENCES CORPORATION (NASDAQ:EXAS)

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline. It has developed a non invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a non invasive stool based deoxyribonucleic acid (DNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody based fecal immunochemical test. The United States Food and Drug Administration (FDA) approved Cologuard for use as sDNA non-invasive colorectal cancer screening test. Cologuard is available through healthcare providers. It also focused on developing its pipeline for future products and services.

An ad to help with our costs